ArticleNPJ breast cancer2023

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.

Ming Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.